Previous 10 | Next 10 |
The following slide deck was published by Twist Bioscience Corporation in conjunction with this event. For further details see: Twist Bioscience (TWST) Presents at the AGBT Conference 2022 - Slideshow
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at th...
-- Twist MRD Rapid 500 Panel Enables Customers to Implement Fully Customizable Panels for $50 per Sample -- – Targets up to 500 Genomic Regions, Enables Unmatched Response Time – – MRD Testing Applications Include Cancer Therapy Response Monitoring and Disea...
Twist Bioscience (NASDAQ:TWST) on Tuesday announced the launch of its Human Methylome Panel, a product that can advance applications in cancer metastasis, human development and functional genetics. The company said its Twist Human Methylome Panel can also be used as a discovery tool to i...
Panel covers 84.2% of CpG islands New tool supports discovery of differentially methylated regions and epigenetic target identification for cancer metastasis and human development research Human methylome panel facilitates development of liquid biopsy panels Twist Bios...
Today, we put Twist Bioscience in the spotlight for the first time. The stock has lost approximately two-thirds of its market value in 2022 despite posting better than expected quarterly results earlier this month. A full investment analysis follows in the paragraphs below. ...
German biotech, Centogene (NASDAQ:CNTG) announced on Wednesday that its CentoCloud cloud-based Software as a Service ((SaaS)) platform for clinical decision making is now CE-marked in Europe under the In Vitro Diagnostics Directive. Europe's new In Vitro Diagnostic Regulation takes effect tom...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Biosc...
PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quar...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will participate i...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...